[Insulinoma].
Insulinoma is considered the most common endocrine tumour of the pancreas with an annual prevalence of 4 cases per million people. Contrary to the other endocrine tumours of this organ, over 90% of the insulinomas are benign in nature. The clinical presentation of this neoplasm depends on excessive production of insulin and pro-insulin and is characterised by the symptoms of neuroglycopenia and catecholamine response. Effective management requires directed biochemical testing, careful choice of preoperative imaging tests, and complete pancreatic exploration by an experienced endocrine surgeon utilising intraoperative ultrasound. The only curative treatment for insulinoma is complete resection of the tumour. The aim of this paper is to critically discuss contemporary diagnosis and treatment of this neoplasm on the basis of progress made in recent years.
Krysiak
Robert
R
Department of Clinical Pharmacology, Silesian Medical University of Katowice, Poland. r.krysiak@pharmanet.com.pl
Okopień
Bogusław
B
Herman
Zbigniew Stanisław
ZS
D007516:Adenoma, Islet Cell / Q000150:complications* / Q000175:diagnosis* / Q000378:metabolism / Q000601:surgery; D003937:Diagnosis, Differential; D013507:Endocrine Surgical Procedures / Q000379:methods; D015408:Gastrinoma / Q000150:complications / Q000175:diagnosis / Q000378:metabolism / Q000601:surgery; D006801:Humans; D007003:Hypoglycemia / Q000150:complications; D007328:Insulin / Q000378:metabolism; D007340:Insulinoma / Q000150:complications* / Q000175:diagnosis* / Q000378:metabolism / Q000601:surgery; D010180:Pancreatectomy / Q000379:methods; D010190:Pancreatic Neoplasms / Q000145:classification / Q000175:diagnosis* / Q000601:surgery; D011379:Prognosis; D035583:Rare Diseases
D007328:Insulin